Sanofi Reports H1 2021 Revenue of €17.3 Billion, Driven by Dupixent Sales of €2.29 Billion

By | Shuye

On July 29, Sanofi reported its first-half 2021 financial results, with total revenue reaching €17.3 billion. Specifically, the Pharmaceuticals business generated €13.2 billion (+1.4%), the Vaccines business €1.94 billion (+5.5%), and the Consumer Healthcare business €2.2 billion (5.2%). While all three business segments experienced a broad-based recovery in the second quarter, constrained by first-quarter sales performance, overall revenue for the first half of 2021 remained essentially flat year-on-year (+0.9%).

Specifically, Sanofi reported Q2 net sales of €8.744 billion, up 12% year-on-year. Dupixent (dupilumab), a blockbuster drug for the treatment of atopic dermatitis and asthma, grew 57% to €1.243 billion, with first-half sales revenue reaching €2.29 billion.

Maintaining its market dominance, Dupixent (dupilumab) will remain Sanofi's most critical product in the short term. During the first half of the year, Dupixent reported positive clinical data for moderate-to-severe asthma in children aged 6 to 11 years, and a supplemental Biologics License Application (sBLA) was submitted, with regulatory approval expected in the second half of the year. However, the leading position of Dupixent (dupilumab) may soon face challenges. In the asthma therapeutic area, tezepelumab, co-developed by Amgen and AstraZeneca, will emerge as a key competing force; meanwhile, the atopic dermatitis landscape continues to see a steady influx of innovative products, including the JAK inhibitor abrocitinib. Despite a recent FDA approval delay, abrocitinib has already demonstrated success in head-to-head clinical trials.

Although the PD-1 monoclonal antibody Libtayo (cemiplimab) and the CD38 monoclonal antibody Sarclisa (isatuximab) are still in a phase of explosive growth, their base remains small, and whether they will become blockbuster drugs remains unclear.

Conversely, the vaccine division has become the fastest-growing segment within Sanofi's "Billion-Euro Club," achieving a 10% increase in the first half of the year. Meanwhile, Nirsevimab, the first extended-half-life monoclonal antibody co-developed with AstraZeneca, also yielded positive results in the first half of the year for the prevention of RSV infection in infants.

It can be said that, reviewing Sanofi's recent product pipeline development strategy, despite a robust lineup of highly anticipated innovative products, their market launch remains some time away. In the short term, the market performance of Dupixent (dupilumab) will be critical to Sanofi's financial results.